Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1051164 | 1.00 | CREBBP (0.50) | CREBBPHTTSLC22A6POLBALDH1A1 | |
| SCHEMBL17023492 | 0.87 | CREBBP (0.48) | CREBBPHTTPOLBALDH1A1KDM4E | |
| SCHEMBL27449574 | 0.82 | L3MBTL1 (0.54) | CREBBPHTTSLC22A6MEN1KMT2A | |
| SCHEMBL10698031 | 0.81 | NR4A2 (0.53) | HTTSLC22A6POLBALDH1A1KDM4E | |
| SCHEMBL17320137 | 0.80 | BAZ2B (0.42) | CREBBPHTTSLC22A6POLBALDH1A1 | |
| SCHEMBL13834151 | 0.80 | NPC1 (0.42) | CREBBPHTTSLC22A6POLBALDH1A1 | |
| SCHEMBL19233806 | 0.80 | CREBBP (0.47) | CREBBPHTTPOLBALDH1A1KDM4E | |
| SCHEMBL2253255 | 0.79 | ALDH1A1 (0.49) | SLC22A6ALDH1A1NPSR1MEN1KMT2A | |
| SCHEMBL25338189 | 0.78 | PDGFRA (0.43) | CREBBPHTTSLC22A6ALDH1A1KDM4E | |
| SCHEMBL2470098 | 0.78 | LMNA (0.40) | CREBBPHTTSLC22A6ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085042-A1 | METHOD FOR PREPARING INDIGO OR A SUBSTITUTED DERIVATIVE THEREOF | PILI (FR) | 2026-03-26 | — | — | US | disclosed |
| CN-113366316-B | Methods and compositions for identifying whether a subject with cancer will acquire a response to an immune checkpoint inhibitor | 国家医疗保健研究所 | 2025-05-23 | — | — | CN | disclosed |
| WO-2024261302-A1 | NLRP3 INHIBITORS, PAK1/2 INHIBITORS AND/OR CASPASE 1 INHIBITORS FOR USE IN THE TREATMENT OF RAC2 MONOGENIC DISORDERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-12-26 | — | — | WO | disclosed |
| CN-115894330-B | Synthesis method and application of 1-acetyl-1H-indol-3-yl acetate derivative | 吉林医药学院 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024231384-A1 | COMPOSITIONS FOR TREATING SENESCENCE RELATED DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-14 | — | — | WO | disclosed |
| EP-4427044-A1 | METHODS AND COMPOSITIONS FOR TREATING TRIPLE NEGATIVE BREAST CANCER (TNBC) | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2024-09-11 | — | — | EP | disclosed |
| EP-4255423-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | Lankenau Institute for Medical Research (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023078900-A1 | METHODS AND COMPOSITIONS FOR TREATING TRIPLE NEGATIVE BREAST CANCER (TNBC) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-05-11 | — | — | WO | disclosed |
| CN-115198018-A | Method for classifying patients with solid cancer | 法国国家卫生及研究医学协会 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022197927-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DRUG RESISTANT TOPICAL INFECTIONS | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-4037710-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OVARIAN CANCER, BREAST CANCER OR PANCREATIC CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-109690314-B | Method for classifying patients with solid cancer | 法国国家卫生及研究医学协会 | 2022-08-02 | — | — | CN | disclosed |
| WO-2022125553-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3956446-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-02-23 | — | — | EP | disclosed |
| EP-3952850-A1 | USE OF SK2 INHIBITORS IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY FOR THE TREATMENT OF CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085042-A1 | METHOD FOR PREPARING INDIGO OR A SUBSTITUTED DERIVATIVE THEREOF | TDO2, IDH2, IDH3A | CREBBP 4341/4885HTT 2716/4885SLC22A6 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.